Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis

Part of paid clinical trials in Morristown, New Jersey.

Sponsor
Atlantic Health System
Study ID
NCT07614321
Phase
PHASE4
Status
Recruiting

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Silodosin 8 mg — DRUG
    Silodosin 8mg PO qd x8 weeks
  • Placebo — DRUG
    Identical placebo capsule, 1 capsule PO daily x8 weeks

Study Details

The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are: Does silodosin improve lower urinary tract symptoms based on questionnaires? Does silodosin change Uroflowmetry parameters in female patients with MS? Researchers will compare silodosin to a placebo (a look-alike substance that contains no drug) to see if silodosin works to treat LUTS in female patients with MS. Participants will: Take silodosin or a placebo every day for 8 weeks Visit the clinic before initiating the medication and after 8 weeks of taking the medication for questionnaires and tests

Key Dates

Start date
Apr 30, 2026
Status verified
May 2026
Primary completion
Mar 31, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Silodosin
    Silodosin 8mg PO daily
  • Placebo Comparator: Placebo
    Identical placebo capsule, 1 capsule PO daily

Primary Outcome Measure

Change in American Urological Association Symptom Score (AUASS) [ Time Frame: From enrollment to the end of treatment at 8 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Atlantic HealthMorristownNew Jersey07960
Mariah McKevitt, MD
973-971-7267

Find similar trials in Morristown, NJ

By condition

Related Studies